EU guidance documents referred to in the Human Medicines Regulations 2012

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Government have updated the Human Medicines Regulations (HMRs) 2012 to address the UK's regulatory framework following its exit from the European Union. These updates, facilitated by the 2019 and 2020 Amendment Regulations, ensure the continued sale and supply of medicines while implementing the Northern Ireland Protocol. Under this system, the MHRA operates independently of the EU network for Great Britain, whereas EU regulations remain applicable in Northern Ireland. To maintain stability, the UK continues to rely on EU guidance documents as they stood immediately before the end of the transition period for England, Scotland, and Wales. This specific document provides a general regulatory update rather than a report on a particular company or inspection; therefore, no specific violations or inspection dates are listed. The framework covers essential areas such as Good Manufacturing Practice (GMP), marketing authorizations, packaging, and pharmacovigilance. Regulated entities are required to adhere to the versions of guidance applicable to their specific region to ensure compliance with human medicine standards. For Great Britain, this involves referencing established pre-transition EU standards, while stakeholders in Northern Ireland must continue to follow current EU requirements as published on European Union websites.